Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
GENELUX CORPORATION Market Cap
From what 0 stock analysts predict, the share price for GENELUX CORPORATION (GNLX) might increase by 641.31% in the next year. This is based on a 12-month average estimation for GNLX. Price targets go from $10 to $32. The majority of stock analysts believe GNLX is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
GENELUX CORPORATION has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that GENELUX CORPORATION will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of GNLX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Benjamin Paluch Roth MKM | Buy | $10 | Initiates | Aug 27, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $32 | Reiterates | Aug 15, 2024 |
| Bruce Jackson Benchmark | Speculative Buy | $25 | Reiterates | Jun 3, 2024 |
| Bruce Jackson Benchmark | Speculative Buy | $25 | Maintains | May 31, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $32 | Reiterates | May 13, 2024 |
| Bruce Jackson Benchmark | Speculative Buy | $30 | Reiterates | Apr 3, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $32 | Maintains | Apr 2, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $35 | Initiates | Nov 27, 2023 |
| Bruce Jackson Benchmark | Speculative Buy | $30 | Maintains | Nov 24, 2023 |
| Jason McCarthy Maxim Group | Buy | $40 | Initiates | Sep 12, 2023 |
| Bruce Jackson Benchmark | Speculative Buy | $38 | Maintains | Jun 9, 2023 |
| Kemp Dolliver Brookline Capital | Hold | $25 | Initiates | May 18, 2023 |
| Bruce Jackson Benchmark | Speculative Buy | $10 | Initiates | Feb 15, 2023 |
When did it IPO
2023
Staff Count
24
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Thomas Zindrick J.D.
Market Cap
$68.4M
In 2023, GNLX generated $170,000 in revenue, which was a decrease of -98.46% from the previous year. This can be seen as a signal that GNLX's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
